CareLit · DOI-Nachweis · Zeitschrift für Phytotherapie
Clinical study data on the safety of isopropanolic extract of Cimicifuga racemosa allow for its unlimited use according to ICH-E1
DOI 10.1055/s-0035-1565967
Bibliografische Angaben
Nachweis in CareLit
Autor:innenHH Henneicke-von Zepelin, S Garcia de Arriba, KU Nolte
ZeitschriftZeitschrift für Phytotherapie
Ausgabe10/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
The duration of use of medicinal products intended for non-life-threatening diseases is directly linked to a positive risk/benefit assessment based on clinical data over distinct exposure periods according ICH-E1 [1]. The HMPC monograph on Cimicifuga racemosa (CR) addressing ethanolic and isopropanolic extract of CR [2] states “Cimicifuga should not be taken for more than 6 months without medical advice”. Based on t…
Zitieren
Zitierempfehlung
HH Henneicke-von Zepelin, S Garcia de Arriba, KU Nolte (2015) Clinical study data on the safety of isopropanolic extract of Cimicifuga racemosa allow for its unlimited use according to ICH-E1. Zeitschrift für Phytotherapie (10). https://doi.org/10.1055/s-0035-1565967
Mit CareLit weiterarbeiten